Impact of Glycemic Control After Reperfusion on Acute Kidney Injury in Living Donor Liver Transplantation

NCT06320730 | Completed

• 1 other identifier: 2020-0675
• Study Type: observational
• Target: 3,790
• Locations: 1 country
• Sites: 1

Brief Summary

This retrospective cohort study of patients classified by the blood glucose level after reperfusion in liver transplantation repicient. Our object is to investigate whether controlling BG levels within the optimal range during neohepatic phase is associated with a reduction of AKI incidence. Furthermore, severe AKI, chronic kidney disease (CKD), major adverse cardiac event (MACE) and mortality were also investigated.

Conditions

Acute Kidney Injury; Hyperglycemia; Hypoglycemia; End Stage Liver Disease

Outcome Measures

Primary Outcomes (1)

• incidence of acute kidney injury

  determined by change in sCr according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition (increase in sCr of ≥26.5 mmol litre-1 within 48h or ≥1.5 times baseline within 7 days after surgery)

  within 7 days after surgery

Secondary Outcomes (4)

• incidence of severe AKI

  within 7 days after surgery

• incidence of chronic kidney disease (CKD)

  within 1 year after surgery

• incidence of Major adverse cardiac event (MACE)

  within postoperative 30 days (POD30)

• overall mortality

  the mortality at overall period (calculated from the date of surgery to the last follow-up) from the date of surgery (up to 10 years)

Study Arms (2)

Group 110 < REP BG < 180

Those with blood glucose levels over 110 and under 180 after reperfusion in liver transplantation recipients.

Other: Observational study, records of blood glucose level after reperfusion

Group REP BG ≤110 or ≥180

Those with blood glucose levels below 110 or above 180 after reperfusion in liver transplantation recipients.

Interventions

Observational study, records of blood glucose level after reperfusion OTHER

Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.

Group 110 < REP BG < 180

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

living donor liver transplant recipients at Asan Medical Center, Seoul, Korea, Republic of Korea, from January 2008 to December 2019.

You may qualify if:

• Living donor liver transplantation recipients

Sponsors & Collaborators

• Asan Medical Center: lead

Study Sites (1)

Jun-Gol Song

Seoul, Song-pa Gu, 05500, South Korea

Location

MeSH Terms

Conditions

Acute Kidney Injury; Hyperglycemia; Hypoglycemia; End Stage Liver Disease

Interventions

Observation

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Liver Failure; Hepatic Insufficiency; Liver Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 8, 2024
• First Posted: March 20, 2024
• Study Start: August 25, 2020
• Primary Completion: August 29, 2020
• Study Completion: March 1, 2021
• Last Updated: March 20, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)